pembrolizumab,enfortumab vedotin,durvalumab,nivolumab,tremelimumab,gemcitabine,avelumab,ipilimumab
astellas,merck,astrazeneca,bms,pfizer,seagen,roche,takeda
['linrodostat', 'vedo', 'avelumab', 'mibc', 'ev 103', 'pembro', 'atezo', ' vedo', 'cisplatin', 'ipi/', 'durva', 'key,note,866', 'niagara', 'enfortumab', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'volga', 'biomarker', 'nivo', 'bladder']
how to improve oncological outcomes, what will we learn or not learn from current trials #gu23 #medtwitter #bladdercancer 
On the road!
Pursuing to improve global health through sharing knowledge, cancer prevention, and care.  
Medical oncologist @AnkaraUni